Advertisement

Drug Delivery and Translational Research

, Volume 8, Issue 3, pp 580–590 | Cite as

Dissolution and oral bioavailability enhancement of praziquantel by solid dispersions

  • Yanyan Liu
  • Tianzi Wang
  • Wenya Ding
  • Chunliu Dong
  • Xiaoting Wang
  • Jianqing Chen
  • Yanhua Li
Original Article
  • 157 Downloads

Abstract

The aim of the present investigation was to enhance the solubility, dissolution, and oral bioavailability of praziquantel (PZQ), a poorly water-soluble BCS II drug (Biopharmaceutical Classification System), using a solid dispersion (SD) technique involving hydrophilic copolymers. The SD formulations were prepared by a solvent evaporation method with PZQ and PEG 4000 (polyethylene glycol 4000), PEG 6000, or P 188 polymers at various weight ratios or a combination of PEG 4000/P 188. The optimized SD formulation, which had the highest solubility in distilled water, was further characterized by its surface morphology, crystallinity, and dissolution in 0.1 M HCl with 0.2% w/v of sodium dodecyl sulfate (SDS). X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR) revealed the amorphous form of PZQ in the SDs. Moreover, at an oral dosage of 5 mg/kg PZQ, the SDs had higher Cmax values and areas under the curve (AUCs) compared to those of commercial PZQ tablets. Preparation of PZQ-loaded SDs using PEG 4000/P 188 is a promising strategy to improve the oral bioavailability of PZQ.

Keywords

Praziquantel Solid dispersion Dissolution Bioavailability Solubility 

Notes

Funding information

This research was supported by the Key Laboratory of Animal Disease Control and Prevention ordinary (120105) operated by Northeast Agricultural University and also supported by the Supporting Program for Sci & Tech Research of China (2015BAD11B03-07) and by the earmarked fund for China Agriculture Research System (CARS-35).

Compliance with ethical standards

The study was performed according to the Guiding Principles in the Use of Animals in Toxicology, as amended in 2008 by the Society of Toxicology.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Supplementary material

13346_2018_487_MOESM1_ESM.docx (37 kb)
ESM 1 (DOCX 36 kb)
13346_2018_487_MOESM2_ESM.docx (95 kb)
ESM 2 (DOCX 95 kb)

References

  1. 1.
    Chaud MV, Lima AC, MMDC V, Paganelli MO, Paula FC, Pedreiro LN, et al. Development and evaluation of praziquantel solid dispersions in sodium starch glycolate. Trop J Pharm Res. 2013;12(2):163–8.  https://doi.org/10.4314/tjpr.v12i2.5. Google Scholar
  2. 2.
    Dinora GE, Julio R, Nelly C, Lilian YM, Cook HJ. In vitro characterization of some biopharmaceutical properties of praziquantel. Int J Pharm. 2005;295(1–2):93–9.  https://doi.org/10.1016/j.ijpharm.2004.01.033. CrossRefGoogle Scholar
  3. 3.
    Passerini N, Albertini B, Perissutti B, Rodriguez L. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. Int J Pharm. 2006;318(1–2):92–102.  https://doi.org/10.1016/j.ijpharm.2006.03.028.CrossRefPubMedGoogle Scholar
  4. 4.
    Cheng L, Lei L, Guo SR. In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends. Int J Pharm. 2010;387(1–2):129–38.  https://doi.org/10.1016/j.ijpharm.2009.12.010. CrossRefPubMedGoogle Scholar
  5. 5.
    Parrot-Lopez H, Perret F, Bertino-Ghera B. Les cyclodextrines amphiphiles et leurs applications. Élaboration de nanoparticules de cyclodextrines amphiphiles pour des applications biomédicales. Ann Pharm Fr. 2010;68(1):12–26.  https://doi.org/10.1016/j.pharma.2009.12.002.CrossRefPubMedGoogle Scholar
  6. 6.
    Xu XM, Khan MA, Burgess DJ. A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. Int J Pharm. 2012;426(1–2):211–8.  https://doi.org/10.1016/j.ijpharm.2012.01.030.CrossRefPubMedGoogle Scholar
  7. 7.
    Rodrigues SG, Chaves ID, de Melo NFS, de Jesus MB, Fraceto LF, Fernandes SA, et al. Computational analysis and physico-chemical characterization of an inclusion compound between praziquantel and methyl-beta-cyclodextrin for use as an alternative in the treatment of schistosomiasis. J Incl Phenom Macrocycl Chem. 2011;70(1–2):19–28.  https://doi.org/10.1007/s10847-010-9852-y.CrossRefGoogle Scholar
  8. 8.
    Cheng L, Guo SR, Wu WP. Characterization and in vitro release of praziquantel from poly(epsilon-caprolactone) implants. Int J Pharm. 2009;377(1–2):112–9.  https://doi.org/10.1016/j.ijpharm.2009.05.007.CrossRefPubMedGoogle Scholar
  9. 9.
    Mourao SC, Costa PI, Salgado HRN, Gremiao MPD. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm. 2005;295(1–2):157–62.  https://doi.org/10.1016/j.ijpharm.2005.02.009.CrossRefPubMedGoogle Scholar
  10. 10.
    Gurunath S, Kumar SP, Basavaraj NK, Patil PA. Amorphous solid dispersion method for improving oral bioavailability of poorly water-soluble drugs. J Pharm Res. 2013;6(4):476–80.  https://doi.org/10.1016/j.jopr.2013.04.008.Google Scholar
  11. 11.
    Giri TK, Kumar K, Alexander A, Ajazuddin BH, Tripathi DK. A novel and alternative approach to controlled release drug delivery system based on solid dispersion technique. Bull Facul Pharmacy Cairo Univ. 2012;50(2):147–59.  https://doi.org/10.1016/j.bfopcu.2012.07.002.CrossRefGoogle Scholar
  12. 12.
    Shi N-Q, Lei Y-S, Song L-M, Yao J, Zhang X-B, Wang X-L. Impact of amorphous and semicrystalline polymers on the dissolution and crystallization inhibition of pioglitazone solid dispersions. Powder Technol. 2013;247:211–21.  https://doi.org/10.1016/j.powtec.2013.06.039.CrossRefGoogle Scholar
  13. 13.
    Frizon F, Eloy JD, Donaduzzi CM, Mitsui ML, Marchetti JM. Dissolution rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent methods. Powder Technol. 2013;235:532–9.  https://doi.org/10.1016/j.powtec.2012.10.019.CrossRefGoogle Scholar
  14. 14.
    Frizon F, Eloy JDO, Donaduzzi CM, Mitsui ML, Marchetti JM. Dissolution rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent methods. Powder Technol. 2013;235:532–9.  https://doi.org/10.1016/j.powtec.2012.10.019.CrossRefGoogle Scholar
  15. 15.
    M E-B, G F, M F. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2009;17(3):217.  https://doi.org/10.1016/j.jsps.2009.08.006.Google Scholar
  16. 16.
    Castro SG, Bruni SS, Lanusse CE, Allemandi DA, Palma SD. Improved albendazole dissolution rate in Pluronic 188 solid dispersions. AAPS PharmSciTech. 2010;11(4):1518–25.  https://doi.org/10.1208/s12249-010-9517-6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Moneghini M, Kikic I, Voinovich D, Perissutti B, Filipović-Grcić J. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution. Int J Pharm. 2001;222(1):129–38.  https://doi.org/10.1016/S0378-5173(01)00711-6.CrossRefPubMedGoogle Scholar
  18. 18.
    Herrmann S, Winter G, Mohl S, Siepmann F, Siepmann J. Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J Control Release. 2007;118(2):161–8.  https://doi.org/10.1016/j.jconrel.2006.11.001.CrossRefPubMedGoogle Scholar
  19. 19.
    Verheyen S, Blaton N, Kinget R, Mooter GVD. Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int J Pharm. 2002;249(1–2):45–58.  https://doi.org/10.1016/S0378-5173(02)00532-X.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhai H, Li S, Andrews G, Jones D, Bell S, Walker G. Nucleation and growth in fluidised hot melt granulation. Powder Technol. 2009;189(2):230–7.  https://doi.org/10.1016/j.powtec.2008.04.021.CrossRefGoogle Scholar
  21. 21.
    Vilhelmsen T, Eliasen H, Schaefer T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. Int J Pharm. 2005;303(1–2):132–42.  https://doi.org/10.1016/j.ijpharm.2005.07.012.CrossRefPubMedGoogle Scholar
  22. 22.
    Guo MR, Fu Q, Wu CN, Guo ZB, Li M, Sun J, et al. Rod shaped nanocrystals exhibit superior in vitro dissolution and in vivo bioavailability over spherical like nanocrystals: a case study of lovastatin. Colloids Surf B-Biointerfaces. 2015;128:410–8.  https://doi.org/10.1016/j.colsurfb.2015.02.039.CrossRefPubMedGoogle Scholar
  23. 23.
    Lowe S, Sher E, Wishart G, Jackson K, Yuen E, Brittain C, et al. An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs. Drug Deliv Transl Res. 2017;7(1):11–5.  https://doi.org/10.1007/s13346-016-0325-8.CrossRefPubMedGoogle Scholar
  24. 24.
    Li ZB, Zhang WJ, Gao Y, Xiang RW, Liu Y, Hu MM, et al. Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs. Drug Deliv Transl Res. 2017;7(1):100–10.  https://doi.org/10.1007/s13346-016-0342-7.CrossRefPubMedGoogle Scholar
  25. 25.
    Bolourchian N, Mahboobian MM, Dadashzadeh S. The effect of PEG molecular weights on dissolution behavior of simvastatin in solid dispersions. Iran J Pharm Res. 2013;12:9–18.Google Scholar
  26. 26.
    Oelmeier SA, Dismer F, Hubbuch J. Molecular dynamics simulations on aqueous two-phase systems—single PEG-molecules in solution. BMC Biophys. 2012;5(1):14.  https://doi.org/10.1186/2046-1682-5-14.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Dhore PW, Dave VS, Saoji SD, Gupta D, Raut NA. Influence of carrier (polymer) type and drug-carrier ratio in the development of amorphous dispersions for solubility and permeability enhancement of ritonavir. 2017.Google Scholar
  28. 28.
    Leonardi D, Barrera MG, Lamas MC, Salomon CJ. Development of prednisone: polyethylene glycol 6000 fast-release tablets from solid dispersions: solid-state characterization, dissolution behavior, and formulation parameters. AAPS PharmSciTech. 2007;8(4):221–8.  https://doi.org/10.1208/pt0804108.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Essa EA, Balata GF. Preparation and characterization of domperidone solid dispersions. Pak J Pharm Sci. 2012;25(4):783–91.PubMedGoogle Scholar
  30. 30.
    Castro SG, Bruni SFS, Urbizu LP, Confalonieri A, Ceballos L, Lanusse CE, et al. Enhanced dissolution and systemic availability of albendazole formulated as solid dispersions. Pharm Dev Technol. 2013;18(2):434–42.  https://doi.org/10.3109/10837450.2012.693509.CrossRefPubMedGoogle Scholar
  31. 31.
    Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics & Biopharmaceutics Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E V. 2000;50(1):47–60.  https://doi.org/10.1016/S0939-6411(00)00076-X.Google Scholar
  32. 32.
    Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14(12):1691.CrossRefPubMedGoogle Scholar
  33. 33.
    Tang XC, Pikal MJ, Taylor LS. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res 2002;19(4):477, 483, DOI:  https://doi.org/10.1023/A:1015147729564.
  34. 34.
    Sethia S, Squillante E. Solid dispersion of carbamazepine in PVPK30 by conventional solvent evaporation and supercritical methods. Int J Pharm. 2004;272(1–2):1–10.  https://doi.org/10.1016/j.ijpharm.2003.11.025.CrossRefPubMedGoogle Scholar
  35. 35.
    Fernández M, Margarit MV, Rodríguez IC, Cerezo A. Dissolution kinetics of piroxicam in solid dispersions with polyethylene glycol 4000. Int J Pharm. 1993;98(1–3):29–35.  https://doi.org/10.1016/0378-5173(93)90037-G.CrossRefGoogle Scholar
  36. 36.
    Margarit MV, Rodríguez IC, Cerezo A. Physical characteristics and dissolution kinetics of solid dispersions of ketoprofen and polyethylene glycol 6000. Int J Pharm. 1994;108(2):101–7.  https://doi.org/10.1016/0378-5173(94)90320-4.CrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2018

Authors and Affiliations

  • Yanyan Liu
    • 1
    • 2
  • Tianzi Wang
    • 1
    • 3
  • Wenya Ding
    • 1
    • 2
  • Chunliu Dong
    • 1
    • 2
  • Xiaoting Wang
    • 1
    • 2
  • Jianqing Chen
    • 1
    • 2
  • Yanhua Li
    • 1
    • 2
  1. 1.College of Veterinary MedicineNortheast Agricultural UniversityHarbinPeople’s Republic of China
  2. 2.Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical DevelopmentHarbinChina
  3. 3.Daxing District Center of Animal Disease ControlBeijingChina

Personalised recommendations